Form 4: Pfizer Director James C. Smith Acquires Additional Phantom Stock Units

Pfizer Director James C. Smith has acquired 1,856.436 phantom stock units as part of deferred director's compensation, increasing his beneficial ownership to 157,093.034 units.

Summary

• James C. Smith, a Director of Pfizer Inc. (PFE), acquired 1,856.436 phantom stock units.
• The transaction date for this acquisition was June 30, 2025.
• Each phantom stock unit was valued at $24.24.
• Following this transaction, James C. Smith beneficially owns a total of 157,093.034 phantom stock units.
• These units represent deferred director's compensation, including dividend equivalents, and are settled in cash or common stock at the director's election upon retirement from the Board of Directors.

Sentiment

Score: 7

Explanation: The acquisition of phantom stock units by a director, even as part of compensation, generally indicates alignment of interests and a long-term commitment to the company's performance.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of Pfizer Inc.

Future Outlook

The phantom stock units are designed to be settled in cash or common stock upon the director's retirement from the Board, indicating a long-term incentive structure.

Industry Context

This Form 4 filing details a routine insider transaction related to director compensation, which is a common practice in the pharmaceutical industry to align the interests of board members with those of shareholders. Such equity-based compensation is a standard component of remuneration packages for directors at large publicly traded companies.

Comparison to Industry Standards

• Director compensation packages in the pharmaceutical industry, including those at major players like Johnson & Johnson (JNJ) or Merck & Co. (MRK), frequently incorporate equity-based awards such as phantom stock units or restricted stock units.
• These awards serve to align the long-term interests of directors with shareholder value, a practice widely adopted across global benchmarks for corporate governance and executive compensation.
• The specific value and number of units granted are typically benchmarked against peer group compensation data to ensure competitiveness and appropriateness for a company of Pfizer's size and market position.

Related Party Transactions

• The acquisition of phantom stock units by a director from the company constitutes a related party transaction, as it involves compensation provided by the issuer to a member of its board of directors.

Stakeholder Impact

• Shareholders: The transaction further aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decision-making.

Next Steps

• Settlement of the phantom stock units will occur upon James C. Smith's retirement from the Board of Directors, at which point they will be converted into cash or common stock based on his election.

Key Dates

Recommendation

Keywords

Pfizer, PFE, Form 4, Insider Transaction, Director Compensation, Phantom Stock Units, SEC Filing, James C. Smith